Supplementary Figure SF4 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
posted on 2023-04-04, 02:01authored byAndres Chang, Akil Akhtar, Lilin Lai, Victor M. Orellana-Noia, Susanne L. Linderman, Ashley A. McCook-Veal, Jeffrey M. Switchenko, Manpreet Saini, Rajesh M. Valanparambil, Kristie A. Blum, Pamela B. Allen, Mary Jo Lechowicz, Jason T. Romancik, Amy Ayers, Alyssa Leal, Colin B. O'Leary, Michael C. Churnetski, Katelin Baird, Melissa Kives, Jens Wrammert, Ajay K. Nooka, Jean L. Koff, Madhav V. Dhodapkar, Mehul S. Suthar, Jonathon B. Cohen, Rafi Ahmed
Supplemental Figure 4. Anti-spike binding IgG titers after booster correlate with conventional B cell numbers in the blood prior booster.
Funding
HHS | National Institutes of Health (NIH)
EU | Winship Cancer Institute (Winship Cancer Institute of Emory University)
American Society of Hematology (ASH)
Leukemia and Lymphoma Society (LLS)
EU | School of Medicine, Emory University (Emory University School of Medicine)
History
ARTICLE ABSTRACT
Limited data exist on antibody responses against current SARS-CoV-2 variants after booster vaccination in patients with NHL/CLL. We showed inferior antibody responses against Omicron variants after booster vaccination in these patients but some generated anti-Omicron titers. This stresses the importance of vaccinating patients with updated formulations.